Select Publications
Journal articles
2013, 'Clinical and molecular characterization of HER2 amplified-pancreatic cancer', Genome Medicine, 5, pp. 78, http://dx.doi.org/10.1186/gm482
,2013, 'Peer relationships and the biomedical doctorate: A key component of the contemporary learning environment', Journal of Higher Education Policy and Management, 35, pp. 370 - 385, http://dx.doi.org/10.1080/1360080X.2013.812055
,2013, 'From functional genomics to precision medicine: The therapeutic potential of targeting ROCK signaling in pancreatic cancer.', Journal of Clinical Oncology, 31, pp. e15029 - e15029, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e15029
,2013, 'Perceived assessment requirements in the contemporary biomedical doctorate: A case-study from a research intensive australian university', International Journal of Doctoral Studies, 8, pp. 105 - 120, http://dx.doi.org/10.28945/1893
,2013, 'Signatures of mutational processes in human cancer', Nature, 500, pp. 415 - 421, http://dx.doi.org/10.1038/nature12477
,2013, 'Erratum: Signatures of mutational processes in human cancer', Nature, 502, pp. 258 - 258, http://dx.doi.org/10.1038/nature12666
,2013, 'Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater', Journal of Clinical Oncology, 31, pp. 1348 - 1356, http://dx.doi.org/10.1200/JCO.2012.46.8868
,2012, 'Impact of intertumoral heterogeneity on predicting chemotheraphy response of BRCA1-deficient mammary tumors', Cancer Research, 72, pp. 2350 - 2361, http://dx.doi.org/10.1158/0008-5472.CAN-11-4201
,2012, 'Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes', Nature, 491, pp. 399 - 405, http://dx.doi.org/10.1038/nature11547
,2012, 'qpure: A tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles', PLoS ONE, 7, pp. e45835, http://dx.doi.org/10.1371/journal.pone.0045835
,2012, 'The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma', Nature, 486, pp. 266 - 270, http://dx.doi.org/10.1038/nature11114
,2011, 'A molecular prognostic nomogram for resectable pancreatic cancer', JOURNAL OF CLINICAL ONCOLOGY, 29, http://dx.doi.org/10.1200/jco.2011.29.4_suppl.154
,2011, 'Molecular pathologic phenotypes and outcome in adenocarcinoma of the ampulla of Vater', JOURNAL OF CLINICAL ONCOLOGY, 29, http://dx.doi.org/10.1200/jco.2011.29.4_suppl.196
,2011, 'A molecular prognostic nomogram for resectable pancreatic cancer.', J Clin Oncol, 29, pp. 154, http://www.ncbi.nlm.nih.gov/pubmed/27985628
,2011, 'Molecular pathologic phenotypes and outcome in adenocarcinoma of the ampulla of Vater.', J Clin Oncol, 29, pp. 196, http://www.ncbi.nlm.nih.gov/pubmed/27985359
,2010, 'High S100A2 Calcium-Binding Protein Expression Defines a Metastatic Phenotype in Pancreatic Cancer', PANCREAS, 39, pp. 1345 - 1346, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000282946600205&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2010, 'Histology and Molecular Pathology Define Clinically Relevant Phenotypes in Carcinoma of the Ampulla of Vater', PANCREAS, 39, pp. 1313 - 1314, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000282946600067&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2010, 'Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo', Cell Cycle, 9, pp. 3804 - 3815, http://dx.doi.org/10.4161/cc.9.18.13002
,2010, 'Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan', Cancer Research, 70, pp. 1700 - 1710, http://dx.doi.org/10.1158/0008-5472.CAN-09-3367
,2010, 'Studying drug resistance using genetically engineered mouse models for breast cancer.', Methods in molecular biology (Clifton, N.J.), 596, pp. 33 - 45, http://dx.doi.org/10.1007/978-1-60761-416-6_3
,2010, 'The contribution of ABC transporters to drug resistance in a realistic mouse mammary tumor model', Cancer Genetics and Cytogenetics, 203, pp. 64 - 64, http://dx.doi.org/10.1016/j.cancergencyto.2010.07.044
,2009, 'Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer', Cancer Research, 69, pp. 6396 - 6404, http://dx.doi.org/10.1158/0008-5472.CAN-09-0041
,2007, 'Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer', Proceedings of the National Academy of Sciences of the United States of America, 104, pp. 12117 - 12122, http://dx.doi.org/10.1073/pnas.0702955104
,2007, 'Nucleus pulposus cellular longevity by telomerase gene therapy', Spine, 32, pp. 1188 - 1196
,2005, 'The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome', Cancer Letters, 228, pp. 241 - 246
,2004, 'Effect of short-term morphine exposure on P-glycoprotein expression and activity in cancer cell lines', Oncology Reports, 11, pp. 1091 - 1095, http://dx.doi.org/10.3892/or.11.5.1091
,1987, 'Tertiary dentine formation in dogs' teeth in response to lining materials.', J Dent, 15, pp. 85 - 87, http://dx.doi.org/10.1016/0300-5712(87)90006-6
,Conference Papers
2023, '1467 Selective targeting of integrins αVβ8 and αVβ1 within the dynamic ecosystem of pancreatic cancer to improve the overall anti-tumor response', in Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, pp. A1631 - A1631, presented at SITC 38th Annual Meeting (SITC 2023) Abstracts, http://dx.doi.org/10.1136/jitc-2023-sitc2023.1467
,2016, 'Combination of CDK4/6 inhibitor PD-0332991 with standard chemotherapy is synergistic in RB high pancreatic cancer', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, pp. S182 - S182, http://dx.doi.org/10.1016/S0959-8049(16)61645-3
,2014, 'Targeted therapies in the treatment of advanced pancreatic adenocarcinoma (PC): A systematic review and meta-analysis of randomized trials', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.e15209
,2014, 'GENOMIC CLASSIFIER FOR PANCREATIC DUCTAL ADENOCARCINOMA THERAPEUTIC RESPONSE', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 44 - 44, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716500009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'PHARMACOLOGIC INTERVENTIONS FOR ADVANCED PANCREATIC CANCER (PC) - A META-ANALYSIS COMPARING GEMCITABINE ALONE (G) VERSUS GEMCITABINE COMBINATIONS (GCs)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 48 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716500014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'MicroRNA-regulated pathways of radiotherapy sensitivity and resistance in breast cancer', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S232 - S232, presented at European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, NETHERLANDS, Amsterdam, 27 September 2013 - 01 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843601304&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'A molecular pre-operative prognostic nomogram for resectable pancreatic cancer', in Cancer Research, American Association for Cancer Research, Washington, DC, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 06 April 2013 - 10 April 2013, http://dx.doi.org/10.1158/1538-7445.AM2013-1156
,2012, 'Abstract B64: A molecular preoperative prognostic nomogram for resectable pancreatic cancer.', in Tumor Biology, American Association for Cancer Research, pp. B64 - B64, presented at Abstracts: AACR Special Conference on Pancreatic Cancer: Progress and Challenges; June 18-21, 2012; Lake Tahoe, NV, http://dx.doi.org/10.1158/1538-7445.panca2012-b64
,2012, 'Identifying Putative MiRNAs Mediators of Radiotherapy Resistance in Breast Cancer', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SPAIN, Barcelona, pp. S270 - S270, presented at 22nd Biennial Congress of the European-Association-for-Cancer-Research, SPAIN, Barcelona, 07 July 2012 - 10 July 2012, http://dx.doi.org/10.1016/S0959-8049(12)71723-9
,2010, 'Abstract A14: Lack of tumor eradication of chemotherapy-sensitive BRCA1;p53-deficient mouse mammary tumors', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. A14 - A14, http://dx.doi.org/10.1158/1078-0432.tcme10-a14
,2010, 'Abstract PL6-1: Resistance to targeted therapies in a realistic mouse breast cancer model', in Clinical Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1078-0432.tcme10-pl6-1
,2006, 'Selective Sensitization of murine tumors to chemotherapy by a novel class of non-toxic small molecule inhibitors of MRP1', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000454606201252&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,Conference Posters
2013, 'From function genomics to precision medicine: the therapeutic potential of targeting rock signalling in pancreatic cancer', Chicago, IL, Vol. 9, pp. 53 - 53, presented at ASCO Annual Meeting, Chicago, IL, 31 May 2013 - 04 June 2013, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000329462300024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,Conference Presentations
2014, 'SOX9 regulates EGFR/ERBB signaling in pancreatic cancer', presented at 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-LB-73
,2014, 'From functional genomics to precision medicine: Using well annotated models to define personalised treatment strategies for pancreatic cancer', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000341276000017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2012, 'Somatic mutations in pancreatic ductal adenocarcinoma using amplicon sequencing from formalin fixed paraffin embedded tissue', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000308642600042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,Conference Abstracts
2024, 'Abstract A029: Re-purposing non-oncology agent itraconazole to target the dynamic cellular ecosystem of pancreatic cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. A029 - A029, http://dx.doi.org/10.1158/1538-7445.panca2023-a029
,2024, 'Abstract B037: Anti-fibrotic FAK ‘priming’ to improve contemporary chemotherapy in pancreatic cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. B037 - B037, http://dx.doi.org/10.1158/1538-7445.panca2023-b037
,2024, 'Abstract C017: The anti-fungal itraconazole improves immunotherapy efficacy in pancreatic ductal adenocarcinoma by reversing the immune-suppressive tumor microenvironment', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. C017 - C017, http://dx.doi.org/10.1158/1538-7445.panca2023-c017
,2017, 'Effect of Rho/ROCK pathway inhibition on metastasis-free and overall survival in biomarker selected, orthotopic, patient-derived models of pancreatic cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 35, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.e15759
,2015, 'Targeting the Rho-ROCK pathway to treat pancreatic cancer: The use of unique preclinical models to ascertain the effects on cancer growth and metastasis', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 33, presented at Gastrointestinal Cancers Symposium, CA, San Francisco, 15 January 2015 - 17 January 2015, http://dx.doi.org/10.1200/jco.2015.33.3_suppl.312
,2013, 'From functional genomics to precision medicine: The therapeutic potential of targeting ROCK signaling in pancreatic cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 31, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419603693&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2012, 'Risk factors for pancreatic cancer in patients with and without a family history of pancreatic cancer', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, Vol. 27, pp. 127 - 127, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000308642600262&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,